Compare PCRX & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | GGN |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 877.0M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | GGN |
|---|---|---|
| Price | $22.51 | $5.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $37.20 | N/A |
| AVG Volume (30 Days) | 579.3K | ★ 605.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $139.00 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $3.93 |
| 52 Week High | $27.99 | $5.88 |
| Indicator | PCRX | GGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 53.15 |
| Support Level | $22.57 | $5.14 |
| Resistance Level | $23.94 | $5.80 |
| Average True Range (ATR) | 0.79 | 0.14 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 49.48 | 92.95 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.